Teleflex Incorporated (NYSE:TFX) Receives $142.43 Consensus PT from Analysts

Teleflex Incorporated (NYSE:TFX) has been assigned a consensus rating of “Reduce” from the twelve research firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $142.4286.

Several analysts recently issued reports on TFX shares. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research note on Monday, December 29th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $135.00 price objective on shares of Teleflex in a report on Wednesday, December 17th. Wells Fargo & Company boosted their target price on shares of Teleflex from $114.00 to $139.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Zacks Research cut shares of Teleflex from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 30th. Finally, Truist Financial boosted their price target on shares of Teleflex from $120.00 to $135.00 and gave the stock a “hold” rating in a research note on Thursday, December 18th.

Teleflex Stock Down 13.1%

Shares of TFX stock opened at $110.00 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.57 and a quick ratio of 1.53. Teleflex has a one year low of $102.58 and a one year high of $185.94. The company’s fifty day moving average price is $118.49 and its 200-day moving average price is $121.15. The company has a market capitalization of $4.86 billion, a price-to-earnings ratio of -14.97, a PEG ratio of 1.41 and a beta of 0.93.

Teleflex (NYSE:TFX) last issued its earnings results on Thursday, November 6th. The medical technology company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $3.38 by $0.29. The company had revenue of $892.90 million during the quarter, compared to the consensus estimate of $892.79 million. Teleflex had a negative net margin of 10.28% and a positive return on equity of 15.64%. Teleflex’s quarterly revenue was up 19.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.49 EPS. Teleflex has set its FY 2025 guidance at 14.000-14.200 EPS. Sell-side analysts expect that Teleflex will post 13.98 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 15th. Investors of record on Friday, November 14th were given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date was Friday, November 14th. Teleflex’s payout ratio is currently -18.50%.

Institutional Trading of Teleflex

A number of large investors have recently added to or reduced their stakes in the company. Thurston Springer Miller Herd & Titak Inc. boosted its position in shares of Teleflex by 242.9% during the 2nd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 216 shares of the medical technology company’s stock valued at $26,000 after acquiring an additional 153 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in Teleflex by 57.9% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock valued at $26,000 after purchasing an additional 77 shares in the last quarter. Hantz Financial Services Inc. raised its stake in Teleflex by 248.8% during the third quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after purchasing an additional 199 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Teleflex during the third quarter valued at $35,000. Finally, True Wealth Design LLC grew its stake in shares of Teleflex by 10,333.3% in the 2nd quarter. True Wealth Design LLC now owns 313 shares of the medical technology company’s stock worth $37,000 after buying an additional 310 shares in the last quarter. Institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.